Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS

被引：0
|
作者：
Lester-Coll, Nataniel Hernan
Benjamin, David Joseph
Ribault, Helene
Foulon, Stephanie
Fizazi, Karim
Rezazadeh, Arash
机构：
[1] Univ Vermont, Larner Coll Med, Burlington, VT USA
[2] Hoag Family Canc Inst, Newport Beach, CA USA
[3] Unicancer, Paris, France
[4] Gustave Roussy Inst, Villejuif, France
[5] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[6] Univ Calif Irvine, Div Hematol Oncol, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [41] ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Crawford, E. David
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
    Wang, Lei
    Li, Chunxing
    Zhao, Zichen
    Li, Xiaojian
    Tang, Chong
    Guan, Zhenpeng
    Sun, Feng
    Gu, Jin
    Li, Ningchen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy
    Ye, Shi-jie
    Huang, Rui-da
    Fei, Xin
    Tao, Zhu-lei
    Liu, Wei-hua
    Ma, Qi
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1188) : 703 - 708
  • [44] Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer.
    Parikh, Neil Rohit
    Nickols, Nicholas George
    Rettig, Matthew
    King, Christopher R.
    Raldow, Ann C.
    Steinberg, Michael L.
    Tran, Phuoc T.
    Kishan, Amar Upadhyaya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] Local therapies for oligometastatic hormone-sensitive prostate cancer
    Falkenbach, Fabian
    Steuber, Thomas
    Graefen, Markus
    UROLOGIE, 2024, 63 (03): : 234 - 240
  • [46] Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis
    Mori, Keiichiro
    Mostafaei, Hadi
    Sari Motlagh, Reza
    Pradere, Benjamin
    Quhal, Fahad
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Kramer, Gero
    Abufaraj, Mohammad
    Karakiewicz, Pierre I.
    Kimura, Takahiro
    Egawa, Shin
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2022, 129 (04) : 423 - 433
  • [47] Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer
    Tierney, Jayne F.
    Vale, Claire L.
    Parelukar, Wendy R.
    Rydzewska, Larysa
    Halabi, Susan
    EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 137 - 143
  • [48] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [49] Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Manarite, Jan
    Muslin, David
    Farrington, Thomas
    Tombal, Bertrand
    FUTURE ONCOLOGY, 2022, 18 (21) : 2585 - 2597
  • [50] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
12345